Italy fines Roche and Novartis

Share this article:

Italy's health ministry has fined Roche and Novartis $1.6 billion for the way in which the two Swiss companies marketed the eye drug Lucentis. The Wall Street Journal reports that the fine comes after a government anti-trust division found the companies “colluded to push doctors toward their jointly marketed Lucentis treatment,” by creating what the WSJ describes as “an artificial distinction between the two products...presenting Avastin as being riskier than Lucentis, in an effort to influence prescriptions.”

The $1.6 billion is for damages the government says covers 2012 to 2014. Novartis and Roche told the WSJ they will appeal the decision.

Roche subsidiary Genentech has also been criticized for its efforts to prod Lucentis prescriptions over those for cheaper Avastin. As the Washington Post reported in December, efforts to discourage doctors from using Avastin in place of Lucentis include marketing tactics, such as packaging the lower-priced medication in difficult-to-break-up quantities and not seeking an official expansion of Avastin's indication, keeping it from officially competing against Lucentis among wet-AMD patients.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.